中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
3期
236-238
,共3页
老年人%贫血,溶血性,自身免疫性%利妥昔单抗
老年人%貧血,溶血性,自身免疫性%利妥昔單抗
노년인%빈혈,용혈성,자신면역성%리타석단항
Elder%Anemia,hemolytic,autoimmune%Rituximab
目的 探讨小剂量利妥昔单抗治疗老年溶血性贫血的疗效及安全性.方法 以37例初诊老年自身免疫性溶血性贫血(AIHA)患者为研究对象,对25例患者应用泼尼松1 mg· kg-1·d-1,4周后评估疗效.对12例因合并各种疾病不能使用泼尼松治疗患者应用利妥昔单抗,每次100mg,每周1次,连用4次后评估疗效.结果 25例泼尼松治疗患者中,完全缓解5例,部分缓解15例,无效5例,完全缓解率20.0％,有效率80.0％.12例给予小剂量利妥昔单抗治疗患者中,完全缓解8例,部分缓解3例,无效1例,完全缓解率66.7％,有效率91.7％.小剂量利妥昔单抗治疗组完全缓解率明显高于泼尼松组,差异有统计学意义(P=0.038).结论 小剂量利妥昔单抗治疗老年AIHA患者安全性、有效性均优于泼尼松.
目的 探討小劑量利妥昔單抗治療老年溶血性貧血的療效及安全性.方法 以37例初診老年自身免疫性溶血性貧血(AIHA)患者為研究對象,對25例患者應用潑尼鬆1 mg· kg-1·d-1,4週後評估療效.對12例因閤併各種疾病不能使用潑尼鬆治療患者應用利妥昔單抗,每次100mg,每週1次,連用4次後評估療效.結果 25例潑尼鬆治療患者中,完全緩解5例,部分緩解15例,無效5例,完全緩解率20.0％,有效率80.0％.12例給予小劑量利妥昔單抗治療患者中,完全緩解8例,部分緩解3例,無效1例,完全緩解率66.7％,有效率91.7％.小劑量利妥昔單抗治療組完全緩解率明顯高于潑尼鬆組,差異有統計學意義(P=0.038).結論 小劑量利妥昔單抗治療老年AIHA患者安全性、有效性均優于潑尼鬆.
목적 탐토소제량리타석단항치료노년용혈성빈혈적료효급안전성.방법 이37례초진노년자신면역성용혈성빈혈(AIHA)환자위연구대상,대25례환자응용발니송1 mg· kg-1·d-1,4주후평고료효.대12례인합병각충질병불능사용발니송치료환자응용리타석단항,매차100mg,매주1차,련용4차후평고료효.결과 25례발니송치료환자중,완전완해5례,부분완해15례,무효5례,완전완해솔20.0％,유효솔80.0％.12례급여소제량리타석단항치료환자중,완전완해8례,부분완해3례,무효1례,완전완해솔66.7％,유효솔91.7％.소제량리타석단항치료조완전완해솔명현고우발니송조,차이유통계학의의(P=0.038).결론 소제량리타석단항치료노년AIHA환자안전성、유효성균우우발니송.
Objectives To explore the safety and efficacy of lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia (AIHA).Methods From May 2008 to February 2013,a total of 37 patients with newly diagnosed elderly AIHA patients were enrolled in the study,including 25 cases treated with prednisone 1 mg · kg-1 · d-1 for 4 weeks and 12 cases ineligible for glucocorticoid receiving rituximab (100 mg/week for 4 times).Results Of the 25 patients with conventional glucocorticoid,5 cases (20.0％) were complete remission (CR),15 cases with partial remission (PR) and 5 cases without response.The overall response rate was 80.0％.Of the 12 cases with rituximab,8 cases (66.7％) were CR,3 cases with PR and 1 without response.The overall response rate was 91.7％.A significantly higher CR rate was seen in lower dose of rituximab,as compared to that in conventional glucocorticoid (9=0.038).Conclusion A lower dose of rituximab,with satisfactory safety and efficacy,was better than the conventional glucocorticoid in the treatment of elderly AIHA patients.
